Trials / Withdrawn
WithdrawnNCT04855266
Iron Sucrose in Patients With Iron Deficiency and POTS
A Randomized, Controlled, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Intravenous Iron Sucrose in Patients With Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Accepted
Summary
This study aims to investigate whether the treatment of non-anemic iron deficiency with intravenous iron sucrose will result in decreased symptom reporting and improved cardiovascular indices in patients with Postural Orthostatic Tachycardia syndrome (POTS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sucrose | 5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted |
| DRUG | Placebo | Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL) |
| DIAGNOSTIC_TEST | Tilt Table Test | A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test. |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2023-05-01
- Completion
- 2023-05-01
- First posted
- 2021-04-22
- Last updated
- 2023-06-13
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04855266. Inclusion in this directory is not an endorsement.